| 36th week of 2009 patent applcation highlights part 31 |
| Patent application number | Title | Published |
|---|
| 20090220439 | Hydroxybenzophenone Derivatives - Disclosed are hydroxyphenylbenzophenone derivatives of formula (1), wherein R | 2009-09-03 |
| 20090220440 | Spray Composition for Topical Use for Treating and/or Preventing Herpes Simplex Labial Infections - The present invention relates to a composition for the topical treatment of labial herpes lesions. The composition is based on preparations of officinal plants, with of anti-herpes simplex virus activity, anti-inflammatory and analgesic properties, and on natural purified components that have emollient, healing and covering effects on herpes eruptions. The composition contains essential oils of | 2009-09-03 |
| 20090220441 | Nanoparticulate UV Protectant With Silicon Dioxide Coating - The present invention relates to nanoparticulate UV protectants which are obtainable by hydrothermal treatment of a nanoparticulate metal oxide and subsequent application of a silicon dioxide coating, and to the preparation and use thereof. The present invention furthermore relates to novel compositions, in particular for topical application, which are intended, in particular, for light protection of the skin and/or of the hair against UV radiation, and to the use thereof in the above-mentioned cosmetic application. | 2009-09-03 |
| 20090220442 | SUNSCREEN COMPOSITION COMPRISING A DIBENZOYLMETHANE, AN AMINOHYDROXYBENZOPHENONE, A TRIAZINE AND A TRIAZOLE AS UV FILTERS - The present invention relates to a composition comprising: a) a dibenzoylmethane derivative UV-A absorbing agent, b) a hydroxybenzophenone, c) a triazine derivative, and d) a triazole derivative, and the topical use thereof in protecting mammalian skin or hair from UV radiation. | 2009-09-03 |
| 20090220443 | COMPOSITIONS COMPRISING METATHESIZED UNSATURATED POLYOL ESTERS - Disclosed are petrolatum-like compositions that comprise metathesized unsaturated polyol esters. Also disclosed are emulsions comprising metathesized unsaturated polyol esters. The petrolatum-like compositions may be used as substitutes for petroleum-based petrolatum. The emulsions may be water-in-oil or oil-in-water emulsions and may be suitable for a variety of end uses. | 2009-09-03 |
| 20090220444 | Antiperspirant and Deodorant Compositions with Improved Protective Action - Cosmetic and dermatological antiperspirant and deodorant compositions which have an improved care effect and comprise at least one yoghurt protein and/or at least one hydrolysate of a yoghurt protein and/or at least one N—C | 2009-09-03 |
| 20090220445 | HAIR CARE COMPOSITIONS AND METHODS FOR INCREASING HAIR DIAMETER AND DELIVERING ADDITIONAL BENEFITS - Disclosed in a hair care composition comprising: a hair care composition comprises: A) a hair diameter increasing agent comprising: a xanthine compound; a vitamin B3 compound; and a panthenol compound; B) an additional benefit agent, such additional benefit is selected from the group consisting of hair volume-up, hair conditioning, hair strengthening, scalp sensation, hair color, scent, and mixtures thereof; and C) a carrier. The hair care compositions of the present invention increase hair diameter, and also provide: motivation to consumers to use such compositions for a longer period of time so that consumers can obtain hair diameter increase benefit; and/or at least one additional benefit, while not-compromising the penetration of the hair diameter increasing agent. | 2009-09-03 |
| 20090220446 | METHOD FOR TREATING HAIR - A method of treating one or more hair shafts, each hair shaft including a cuticle layer and a cortex enclosed in the cuticle layer is disclosed. The method comprises: selecting one or more polymers that can penetrate the hair shafts with a pore size of about 5 angstroms to about 5000 angstroms; and treating the hair shafts by applying an effective amount of a composition containing said polymers to said hair shafts. | 2009-09-03 |
| 20090220447 | METHOD FOR TREATING HAIR DAMAGED BY COLOR TREATMENTS - A method of treating one or more hair shafts, each hair shaft including a cuticle layer and a cortex enclosed in the cuticle layer is disclosed. The method comprises: selecting one or more polymers that can penetrate the hair shafts with a pore size of about 5 angstroms to about 5000 angstroms; and treating the hair shafts by applying an effective amount of a composition containing said polymers to said hair shafts. | 2009-09-03 |
| 20090220448 | HAIR CARE COMPOSITIONS AND METHODS FOR INCREASING HAIR DIAMETER AND FOR IMMEDIATE FULLER/THICKER HAIR APPEARANCE - Disclosed in a hair care composition comprising: (i) a deposition agent which is in a solid particulate form on the hair; (ii) an adhesive agent which adhere the deposition agent to the hair; and (iii) an carrier; wherein either or both of the deposition agent and the adhesive agent comprises an agent which increases hair diameter; and wherein, when the deposition agent is the hair diameter increasing agent, such agents are those being substantially soluble in the composition and forming solid particulate on the hair. The hair care compositions of the present invention provide an increase of hair diameters and provide an immediate increase of the fullness and/or thickness of hair appearance. | 2009-09-03 |
| 20090220449 | SUBSTITUTED ORGANOPOLYSILOXANES AND USES THEREOF - The invention relates to new compounds of Formula 1: [(O | 2009-09-03 |
| 20090220450 | Methods and compositions for wound healing - Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair. | 2009-09-03 |
| 20090220451 | CYCLOPROPYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS - Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well. | 2009-09-03 |
| 20090220452 | Method Of Producing A Modified (POLY) Peptide - This invention relates to a method of producing a modified (poly)peptide, said method comprising the step of modifying in an organic solvent a crown ether-bound (poly)peptide at one or more carboxylic groups by esterification or thioesterification and/or at the amino group of the N-terminal amino acid by amidation or alkylation. Furthermore provided are (poly)peptides and antibodies obtainable with the method of the invention as well as medical uses thereof. | 2009-09-03 |
| 20090220453 | ENHANCING STEM CELL MOBILIZATION - This invention relates to methods and compositions for enhancing hematopoietic stem cell mobilization by inhibiting early growth response-1 (egr1) activity. | 2009-09-03 |
| 20090220454 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS - The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed. | 2009-09-03 |
| 20090220455 | PHARMACEUTICAL COMPOSITIONS COMPRISING ELP FUSION PROTEINS - Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods. | 2009-09-03 |
| 20090220456 | USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE - This invention provides a method for preventing or treating Severe Acute Respiratory Syndrome in a subject comprising administering to the subject an effective amount of recombinant super-compound interferon or a functional equivalent thereof. This invention provides a method for inhibiting the causative agent of Severe Acute Respiratory Syndrome comprising contacting the agent with an effective amount of super-compound interferon or its equivalent. | 2009-09-03 |
| 20090220457 | COMBINATIONS COMPRISING HCV PROTEASE INHIBITOR(S) AND HCV IRES INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO - Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of: (a) at least one HCV IRES inhibitor; and (b) at least one HCV protease inhibitor; and optionally (c) at least one other therapeutic agent; for concurrent or consecutive administration in treating or ameliorating one or more symptoms of HCV, or disorders associated with HCV in a subject in need thereof. | 2009-09-03 |
| 20090220458 | PSEUDOTYPED RETROVIRAL VECTORS AND METHODS OF USE THEREOF - The present invention provides nucleic acids encoding recombinant envelope proteins; and packaging cells comprising the nucleic acids, which packaging cells provide for encapsidation of recombinant retroviral vectors. The present invention provides producer cells that produce pseudotyped recombinant retroviral vectors. The present invention further provides methods of purifying pseudotyped recombinant retroviral vectors; and purified pseudotyped recombinant retroviral vectors. The present invention further provides methods of delivering a gene product to an individual. The methods generally involve introducing a subject recombinant retroviral vector into an individual. | 2009-09-03 |
| 20090220459 | NON-PATHOGENIC AND/OR ATTENUATED BACTERIA CAPABLE OF INDUCING APOPTOSIS IN MACROPHAGES, PROCESS OF MANUFACTURING AND USES THEREOF - The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages. | 2009-09-03 |
| 20090220460 | VIRUS STRAINS - The present invention relates to clinical herpes simplex virus (HSV) isolates with improved oncolytic capabilities as compared to reference laboratory HSV strains. The present invention also relates to methods of producing HSV strains of the invention and to pharmaceutical compositions comprising a HSV strain of the invention. | 2009-09-03 |
| 20090220461 | Metastasis inhibition preparations and methods - Disclosed are compositions and pharmaceutical preparations suitable for inhibiting metastasis of a malignant cancer in an animal. Methods for inhibiting and/or eliminating metastasis in an animal are also provided. In some embodiments, the preparations and compositions comprise a whole cell tumor preparation comprising tumor tissue cells and tumor connective tissue stroma. The disclosure also provides methods for preparing the preparations and pharmaceutical preparations. Inhibition of metastasis of malignant prostate cancer to the lung is shown in vivo. | 2009-09-03 |
| 20090220462 | STEM CELLS - The present invention relates, in general, to stem cells and, in particular, to a method of expanding stem cells by inhibiting aldehyde dehydrogenase (ALDH). The invention further relates to methods of identifying compounds suitable for use in effecting expansion of stem cells. | 2009-09-03 |
| 20090220463 | Pharmaceutical Composition For Treating Vascular-Related Diseases Comprising Peptide - Disclosed is a composition for treating vascular diseases by acting on abnormal angiogenesis by means of secretion of angiopoietins. | 2009-09-03 |
| 20090220464 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 2009-09-03 |
| 20090220465 | METHODS AND COMPOSITIONS FOR MODULATION OF STEM CELL AGING - Methods are described for promoting or maintaining self-renewal of a stem cell expressing or expected to express p16 | 2009-09-03 |
| 20090220466 | VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS AND METHODS OF ISOLATING AND USING THE SAME - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject. | 2009-09-03 |
| 20090220467 | USE OF TYPE II PNEUMOCYTES IN THE TREATMENT OF PULMONARY DISEASES ASSOCIATED WITH PULMONARY FIBROSIS - It describes the use of type II pneumocytes as inhibitory agents of fibroblast proliferation, for which reason they can be used in the preparation of a drug for the treatment of lung diseases which present with pulmonary fibrosis. | 2009-09-03 |
| 20090220468 | Specific CD4+CD25+ Regulatory T Cells for Haematopoietic Cell Transplantation and Immune Tolerance - A pharmaceutical composition comprising CD4+ CD25+ regulatory T cells specific for at least one minor histocompatibility antigen, and stem cells, advantageously haematopoietic, carrying at least the antigen can be used as a medicament for increasing the immune tolerance of a histocompatible host. | 2009-09-03 |
| 20090220469 | PEPTIDES AGAINST AUTOANTIBODIES ASSOCIATED WITH GLAUCOMA AND USE OF THESE PEPTIDES - The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides—especially in apheresis—for the treatment of glaucoma. | 2009-09-03 |
| 20090220470 | UBIQUITIN BINDING POLYPEPTIDES - The invention relates to Tandem Ubiquitin Affinity Entities (TUBES) which are fusion polypeptides comprising at least two ubiquitin binding domains connected to each other by non-naturally occurring spacer regions. The TUBES are capable of binding with high affinity to ubiquitin and to ubiquitylated polypeptides and are therefore suitable for the purification of ubiquitylated polypeptides from cellular extracts as well as for the identification of new ubiquitylated polypeptides. | 2009-09-03 |
| 20090220471 | Solution for the biological cleaning of toothbrushes and corresponding device - A solution for the cleaning of toothbrushes consisting of a watery solution with a mixture of non-pathogenic gram-positive bacteria of the | 2009-09-03 |
| 20090220472 | Method for Treating Malignant Melanoma - The present invention discloses an immunotherapeutic method for treating patients suffering from malignant melanoma, by administering expanded tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes obtainable from one or more sentinel or metinel lymph nodes draining a malignant melanoma or a metastasis arising from malignant melanoma. The present invention provides a new effective method for treating malignant melanoma and metastatic malignant melanoma, without adverse side effects associated with the known treatments. The method comprises identification of in a patient one or more sentinel and/or metinel lymph nodes draining a malignant melanoma or a metastasis there from, resection of the one or more nodes and, optionally all or part of the tumour or metastasis, isolation of tumour-reactive T-lymphocytes from said lymph nodes, in vitro expansion of said tumour-reactive T-lymphocytes, and administration of the thus obtained tumour-reactive T-lymphocytes to the patient, wherein the T-lymphocytes are CD4+ helper and/or CD8+ T-lymphocytes. | 2009-09-03 |
| 20090220473 | ADIR RELATED POLYMORPHISMS AND APPLICATIONS THEREOF - The invention relates to the field of stem cell transplantations, immunotherapy and prophylaxis of neoplastic disease. Provided are peptides comprising an amino acid sequence encoded by an open reading frame as present in the nucleotide sequence of a transcript of a naturally occurring hADIR allele, wherein the amino acid sequence comprises a polymorphic MHC class I or II minor histocompatibility binding peptide. | 2009-09-03 |
| 20090220474 | NOVEL A-GALACTOSIDASES - This invention relates to novel α-galactosidases for the enzymatic removal of the immunodominant monosaccharides on blood products and tissues. Specifically this invention provides a novel family of α3 glycosidases, used for the enzymatic removal of type B antigens from blood group B and AB reactive blood products, and the GaIiIi antigen from non-human animal tissues, thereby converting these to non-immunogenic cells and tissues suitable for transplantation. | 2009-09-03 |
| 20090220475 | BONE REPAIR MATERIAL - The bone repair material comprises the following components: | 2009-09-03 |
| 20090220476 | LAGLIDADG HOMING ENDONUCLEASE VARIANTS HAVING MUTATIONS IN TWO FUNCTIONAL SUBDOMAINS AND USE THEREOF - Provided is a LAGLIDADG (SEQ ID NO: 50) homing endonuclease variant having mutations in two separate subdomains, each binding to a distinct part of a modified DNA target half-site, the LAGLIDADG (SEQ ID NO: 50) homing endonuclease variant being able to cleave a chimeric DNA target sequence having nucleotides bound by each subdomain. A heterodimeric meganuclease and derived products for genetic engineering, genome therapy and antiviral therapy are also provided. | 2009-09-03 |
| 20090220477 | PREVENTION OF MICRONUTRIENT DEFICIENCIES ASSOCIATED WITH COMMON DISABILITIES IN THE OVER 50 ADULT - A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B | 2009-09-03 |
| 20090220478 | Pharmaceutical active substance - Pharmaceutical active substance for treating tumors in the area of breast tissue (breast carcinoma) while using peptide toxin, a substance that acts in an antagonistic manner thereto, and/or a penetrating substance extracted from the venom of spiders of the family Lycosa tarantula. | 2009-09-03 |
| 20090220479 | EGLN2 VARIANTS AND USE THEREOF IN PREVENTING OR TREATING THROMBOEMBOLIC DISORDERS AND CORONARY HEART DISEASE - The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction. | 2009-09-03 |
| 20090220480 | CELLULOLYTIC ENZYMES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention provides polypeptides having any cellulolytic activity, e.g., a cellulase activity, a endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a β-xylosidase, an arabinofuranosidase, and/or an oligomerase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, β-xylosidase, arabinofuranosidase, and/or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. In one aspect, the invention provides polypeptides having an oligomerase activity, e.g., enzymes that convert recalcitrant soluble oligomers to fermentable sugars in the saccharification of biomass. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural, food and feed processing and industrial contexts. The invention also provides compositions or products of manufacture comprising mixtures of enzymes comprising at least one enzyme of this invention. | 2009-09-03 |
| 20090220481 | METHOD AND COMPOSITIONS FOR TREATING SKIN - A skin care composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; a method for inhibiting damage to human keratinocytes due to environmental aggressors by applying a composition comprising at least one keratinocyte CLOCK or PER1 gene activator and at least one DNA repair enzyme; and a method for repairing DNA damage in human keratinocytes. | 2009-09-03 |
| 20090220482 | METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST - Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist. | 2009-09-03 |
| 20090220483 | Stable Enzymatic Preparations and Methods of Use Thereof - The present invention relates to stable concentrated enzymatic compositions suitable for storage under ambient conditions, while maintaining their intended enzymatic activity. The invention further relate to kits comprising concentrated enzymatic compositions, methods for preparing debriding solutions from said concentrated enzymatic compositions and methods of using the diluted debriding solutions. | 2009-09-03 |
| 20090220484 | Rage/Diaphanous Interaction and Related Compositions and Methods - This invention provides a polypeptide consisting essentially of all or a portion of the cytoplasmic domain of RAGE. This invention further provides a polypeptide consisting essentially of a portion of Diaphanous that binds to the cytoplasmic domain of RAGE. Additionally, this invention provides related nucleic acids, vectors, cells and methods. | 2009-09-03 |
| 20090220485 | Method for isolation of soluble polypeptides - Polypeptides with desirable biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human VHs and VLs, are identified using a high throughput method for screening polypeptides, comprising the steps of obtaining a phage display library, allowing infection of a bacterial lawn by the library phage, and identifying phage which form larger than average plaques on the bacterial lawn. Sequences of monomeric human VHs and VLs are identified, which may be useful for immunotherapy or as diagnostic agents. Multimer complexes of human VHs and VLs are also identified. The VHs and VLs identified may be used to create further libraries for identifying additional polypeptides. Further, the VHs and VLs may be subjected to DNA shuffling to select for improved biophysical properties. | 2009-09-03 |
| 20090220486 | ANTIBODIES AND USES THEREOF - The present invention provides antibodies or fragments thereof that bind to cancer cells and is important in physiological phenomena, such as cell rolling and metastasis. Therapeutic and diagnostic methods and compositions using such antibody fragments thereof are also provided. The methods and compositions according to the present invention can be used in targeting therapeutic agents and in diagnosis, prognosis, and staging of and therapy for such diseases as cancer, including tumor growth and metastasis, leukemia, auto-immune disease, and inflammatory disease. Also provided is a library of immunoglobulin binding domains having a diverse antigen-binding domain for complementary binding, wherein the library has diversity only in heavy chain CDR3. | 2009-09-03 |
| 20090220487 | Methods and Compositions for Inhibition of Vascular Permeability - The present invention relates to methods and compositions for regulating vascular permeability. The present invention relates to methods and compositions for blocking proteins and signal transduction pathways involved in increasing vascular permeability. | 2009-09-03 |
| 20090220488 | EVALUATING AND TREATING SCLERODERMA - The expression of a number of genes is altered in scleroderma. Therapeutic methods for treating scleroderma can include counteracting the effects of the altered gene expression profile. Further, scleroderma can be diagnosed and monitored by evaluating the expression of one or more of the altered genes. | 2009-09-03 |
| 20090220489 | ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME - The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described. | 2009-09-03 |
| 20090220490 | Compositions and Assays for Inhibiting HCV Infection - The present invention provides isolated compounds, peptides, antibodies, vaccines that inhibit one or more functional domains of HCV E2 protein from interacting with associated proteins selected from the group consisting of AP-50, HSC70, Cyclin A, and Cyclin G. Pharmaceutical compositions and method of use thereof comprising the same for inhibiting HCV infection are also provided. The present invention further provides a primary hepatocyte cell culture comprising hepatocytes from a health individual and bodily fluid from a HCV infected individual, and method of use thereof, for screening compounds for inhibiting HCV infection. | 2009-09-03 |
| 20090220491 | Binding agents which inhibit myostatin - The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity. | 2009-09-03 |
| 20090220492 | PROTEIN PURIFICATION - A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants. | 2009-09-03 |
| 20090220493 | Reagents and methods for inducing an immune response to prostate specific antigen - The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen. | 2009-09-03 |
| 20090220494 | Antibodies produced in a transgenic avian - The invention includes compositions comprising novel forms of glycosylated human interferon-α. | 2009-09-03 |
| 20090220495 | Cancer Related Genes (PRLR) - This invention is in the field of cancer-associated genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of expression of a PRLR gene or protein. The invention also provides methods and molecules for upregulating or downregulating PRLR gene expression and PRLR protein activity. | 2009-09-03 |
| 20090220496 | NOVEL USES FOR ANTI-IGE THERAPY - The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status/with a therapeutically effective amount of an anti-IgE Ênoiety. In accordance with the invention, COFD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found, to be useful ioÊ the treatment of COPD patients regardless of their skin test results arid/or in vitro reactivity to a perennial aeroalleigen. Anti-EgE moieties, in accordance With the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal iirunuitoglobulln E (e.g., human imntnnoglQbulin E) such as humanized arrti-IgEy hmuanized murine monoclonal antibody, and/or Qmalizumab. | 2009-09-03 |
| 20090220497 | THERAPEUTIC COMPOSITIONS COMPRISING HYALURONAN AND THERAPEUTIC ANTIBODIES AS WELL AS METHODS OF TREATMENT - The present invention relates generally to treatment and prophylactic protocols for cellular diseases or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides compositions comprising therapeutic antibodies and hyaluronan and their use in the treatment or prophylaxis of cellular diseases and disorders. | 2009-09-03 |
| 20090220498 | Method for Discovering Inhibitors of the Epstein-Barr Virus-Induced Gene 3 (EBI3) and Derivatives Thereof for the Treatment of Metastasizing Tumors and Allergic Asthma - The present invention relates to a method for identifying inhibitors of the Epstein Barr virus-induced gene 3 (EBI3), a method for producing a pharmaceutical composition, comprising an inhibitor, a respective pharmaceutical composition and a method for treating a metastasizing tumor disease or allergic asthma, comprising the administration of an effective amount of an inhibitor of EBI3. | 2009-09-03 |
| 20090220499 | Agents for Suppressing Damage to Transplanted Islets After Islet Transplantation - The present inventors investigated anti-IL-6 receptor antibodies for their effect in suppressing damage to transplanted islets after islet transplantation. As a result, they found that anti-IL-6 receptor antibodies reduced damage to transplanted islets, improved islet survival, and corrected hyperglycemia in recipients. Further, they revealed that administration of the anti-IL-6 receptor antibodies of the present invention suppressed the production of inflammatory cytokines by infiltrating cells after transplantation. Specifically, the present inventors discovered for the first time that damage to transplanted islets after islet transplantation can be suppressed by using anti-IL-6 receptor antibodies according to the present invention. | 2009-09-03 |
| 20090220500 | AGENTS FOR TREATING CARDIOPATHY - The present inventors investigated the effects of anti-IL-6 receptor antibodies on improving the condition of infarcted areas in myocardial infarction, and on suppressing left ventricular remodeling after myocardial infarction. As a result, the administration of anti-IL-6 receptor antibodies significantly suppressed the increase of MPO activity in the infarcted area and suppressed myocardial MCP-1 expression in both the infarcted area and the non-infarcted area. Furthermore, echocardiography and histological examinations revealed that cardiac hypertrophy is also suppressed. | 2009-09-03 |
| 20090220501 | Anti-CD19 Antibody, Immunotoxin and Treatment Method - Provided is an immunotoxin including (a) an anti-CD19 antibody lacking an Fc fragment, (b) a modified exotoxin A protein having both Domains II and III, but lacking Domain I, and (c) a peptide linker joining the C-terminal end of the antibody to the N-terminal end of the modified exotoxin A protein. The linker is substantially resistant to extracellular cleavage. The modified exotoxin A protein may be further modified to include a C-terminal KDEL sequence (SEQ ID NO: 6) that promotes transport of the protein to the endoplasmic reticulum of cells that have taken up the immunotoxin. Also provided is an anti-CD19 antibody having enhanced binding activity, antibody-dependent cellular cytotoxicity (ADCC) and methods for using the antibody to treat a disease state associated with B-lineage cells that express CD19. The antibody variable light and variable heavy chains have unique sequences in their J region relative to known anti-CD19 antibody sequences. | 2009-09-03 |
| 20090220502 | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS - Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells. | 2009-09-03 |
| 20090220503 | METHOD FOR TREATING CANCERS WITH INCREASED RAS SIGNALING - Disclosed herein are methods for treating a subject with, or at risk for, developing a tumor which has aberrantly increased Ras signaling. The method involves obtaining a biological sample from the subject, determining whether the biological sample contains cells which have aberrantly increased Ras signaling, and administering an agent that selectively inhibits Protein Kinase C (PKC) delta to the subject upon determination of the aberrantly increased Ras signaling, to thereby inhibit PKC-delta in the cell. The increased Ras signaling may result from expression of activated Ras, e.g. resulting from mutations in codon 12, 13, 59, 61, 63, 116, 117, or 146. Such mutations can be determined by detection of a nucleotide sequence encoding an activated form of Ras protein, or by detection of the activated Ras protein. The increased Ras signaling may result from over-expression of wild-type Ras, over-activation of wild-type Ras, or increased activation of one or more effector pathways downstream of Ras. The tumor cells of the individual may be malignant or non-malignant. The inhibitor(s) of PKC-delta may inhibit PKC-delta gene expression, reduce PKC-delta protein levels, and/or inhibit PKC-delta protein function by inhibiting kinase activity. Appropriate inhibitors are Rottlerin, Balanol, balanol analogs, KAI 9S03, and combinations thereof. Also disclosed are methods for determining the likelihood of effectiveness of administering an agent that selectively inhibits PKC-delta to a subject with a tumor. The methods involve determining the presence or absence of aberrantly increased Ras signaling in the tumor, wherein the presence of aberrantly increased Ras signaling indicates that administration of the PKC-delta inhibitor is likely to be effective. | 2009-09-03 |
| 20090220504 | COMBINATORIAL THERAPY - The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them. | 2009-09-03 |
| 20090220505 | METHODS OF INHIBITING AMYLOID TOXICITY - The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit. | 2009-09-03 |
| 20090220506 | HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 2009-09-03 |
| 20090220507 | INHIBITION OF EXTRACELLULAR SIGNAL-REGULATED KINASE 1/2 AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE - The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. The present invention provides the link between ERK1/2 and calcineurin and CamKII. The present invention further demonstrates that inhibitors of ERK1/2 inhibit cardiac hypertrophy and heart disease by inhibiting, in part, the fetal cardiac gene expression that occurs when Ca2+-dependent signalling occurs in the heart. | 2009-09-03 |
| 20090220508 | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement - Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH. | 2009-09-03 |
| 20090220509 | SINGLEC-9 BINDING AGENTS - The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods. | 2009-09-03 |
| 20090220510 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 2009-09-03 |
| 20090220511 | Ifn-alpha/beta-independent mechanism of antiviral protection through a novel ligand-receptor pair: Ifn- ligands engage a novel receptor Ifn-Rn (CRF2-12) and IL-10R2 (CRF2-4) for signaling andinduction of biological activities - A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions. | 2009-09-03 |
| 20090220512 | GENES AND POLYPEPTIDES RELATING TO PROSTATE CANCERS - The present application provides novel human gene ELOVL7 whose expression is markedly elevated in prostate cancers. The gene and polypeptide encoded by the gene can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer. | 2009-09-03 |
| 20090220513 | STREPTOCOCCUS SUIS POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND THEIR USE IN VACCINAL AND DIAGNOSTIC APPLICATIONS - The present invention relates to the field of | 2009-09-03 |
| 20090220514 | ADAM10 and its Uses Related to Infection - The present invention relates to a protein, ADAM10, ADAM10 nucleic acid sequences and ADAM10 proteins encoded by these sequences that are involved in infection by one or more pathogen such as a virus, a parasite, a bacteria or a fungus or are otherwise associated with the life cycle of a pathogen. | 2009-09-03 |
| 20090220515 | TREATMENT AND PREVENTION OF RENAL DISEASE - The present invention is directed to a method of treating or preventing renal disease in a subject. This method involves administering the subject an agent which inhibits FAT10 expression in the subject under conditions effective to prevent or treat renal disease. Also disclosed is a method of screening for agents effective in treating or preventing renal disease. | 2009-09-03 |
| 20090220516 | Neuroprotection of retinal ganglion cells - This invention relates to the neuroprotection of the optic nerve and the treatment of glaucoma, more specifically, the invention is directed to a method of preventing, inhibiting, decreasing incidence and suppressing death in ganglion cells by manipulating the P2X | 2009-09-03 |
| 20090220517 | METHOD FOR PRODUCING EPITOMERS AND THEIR USES ON CARRIER MICROORGANISMS - The present invention relates to a method for producing carrier microorganisms, in particular bacteria, which, through targeted genetic manipulation, carry epitopes or epitomers, respectively, on their surfaces. Epitomers are antigenically effective epitopes that can be found in the polypeptide chain in multiple identical copies, and which, when expressed on the surface of the bacteria, can be used for immunization with particular success. A further aspect relates to correspondingly produced bacteria and their uses as vaccines, in particular in cancer therapy. | 2009-09-03 |
| 20090220518 | METHODS AND COMPOSITIONS FOR TREATMENT OF GRAFT REJECTION AND PROMOTION OF GRAFT SURVIVAL - Embodiments herein illustrate methods of treating, reducing or preventing transplantation rejection and/or side effects associated with transplantation. Some embodiments relate to compositions and methods for inhibition of graft rejection and promotion of graft survival. Other embodiments relate to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. Yet other embodiments relate to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease, derivatives and fragments of the carboxy-terminus of alpha1-antitrypsin and inducers of other alpha1-antitrypsin activities and uses thereof. | 2009-09-03 |
| 20090220519 | ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners. | 2009-09-03 |
| 20090220520 | Recombinant method for the production of a monoclonal antibody to CD52 for the treatment of chronic lymphocytic leukemia - The present invention relates to the recombinant method used for the production of soluble form monoclonal antibody that binds to CD52. The procedure describes the de novo synthesis of the nucleic acid sequence encoding anti-CD 52, transformation of the constructed nucleic acid sequences into competent bacteria and the sub-cloning of the same into mammalian expression vectors for expression of the desired protein. DNA constructs comprising the control elements associated with the gene of interest has been disclosed. The nucleic acid sequence of interest has been codon optimized to permit expression in the suitable mammalian host cells. | 2009-09-03 |
| 20090220521 | Anti MIF Antibodies - The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions. | 2009-09-03 |
| 20090220522 | Detoxified Endotoxin Vaccine and Adjuvant and Uses thereof - The present invention describes a detoxified Gram negative J5 core lipopolysaccharide/group B meningococcal outer membrane protein complex vaccine given in conjunction with CpG 7909 adjuvant. This vaccine composition can be used for either active or passive immunization of mammals for the prevention or treatment of sepsis and infection with Gram negative bacteria. The addition of CpG to the vaccine was shown to markedly increase the antibody response in mice. Furthermore, the ability of the endotoxin vaccine in protecting against Gram-negative bacteria such as | 2009-09-03 |
| 20090220523 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY AND NEOVASCULARIZATION CONDITIONS - The present invention relates to compositions and methods for the treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of the bioactive lipids. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphinxine-1-phosphate (S1P) or lysophosphophatidic acid (LPA). | 2009-09-03 |
| 20090220524 | THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE AND CANCER - To provide a therapeutic drug for Alzheimer's disease and/or a cancer. | 2009-09-03 |
| 20090220525 | Novel Bacterium and Vaccine - The present invention relates to a novel rod-shaped pleiomorphic non-motile Gram-negative bacterium causing a new, deadly, disease in fish, to a microbiological culture comprising said bacterium, to a vaccine comprising said bacterium and methods for the preparation of such a vaccine, to antibodies reactive with said bacterium, to diagnostic test kits and to the use of said bacterium. | 2009-09-03 |
| 20090220526 | ACUTE RENAL INJURY - We disclose a new and useful biomarker for acute kidney injury (i.e., AKI), renal ischemia reperfusion injury (i.e., IRI), ischemic acute kidney injury, and/or ischemic acute tubular necrosis (i.e., ATN). The biomarker is GRO-alpha (i.e., CXCL1, chemokine C-X-C ligand 1, GRO1, GROa, MGSA, MGSA alpha, MGSA-a, NAP-3, SCYB1). We detected the biomarker using a QUANTIKINE® human GRO-alpha immunoassay (Cat. No. DGR00, R & D Systems, Minneapolis, Minn.). In addition, we disclose a method of treating lung damage. | 2009-09-03 |
| 20090220527 | AFFINITY OPTIMIZED EPHA2 AGONISTIC ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy. | 2009-09-03 |
| 20090220528 | Stimulation of Toll-Like Receptors on T Cells - The present invention relates to compositions and methods for modulating Toll-like receptors (TLRs) for enhancing survival of activated CD4+ T cells. The enhanced survival of activated CD4+ T cells provides a means for regulating an immune response. | 2009-09-03 |
| 20090220529 | Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker - This invention relates to the field of antibody-drug conjugates, and more particularly antibody-drug conjugates that are intended for the treatment and/or diagnosis of diseases such as tumors and/or inflammatory reactions. | 2009-09-03 |
| 20090220530 | DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE - Methods are disclosed for producing defective ribosomal products (DRiPs) in blebs (DRibbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. DRibbles can be used to load antigen presenting cells (APCs), thereby allowing the APCs to present the DRiPs and antigenic fragments thereof. Immunogenic compositions that include treated cells, isolated DRibbles, or DRibble-loaded APCs are also disclosed. Methods are also provided for using treated cells, isolated DRibbles, or DRibble-loaded APCs to stimulate an immune response, for example in a subject. For example, DRibbles obtained from a tumor cell can be used to stimulate an immune response against the same type of tumor cells in the subject. In another example, DRibbles obtained from a pathogen-infected cell or cell engineered to express one or more antigens of a pathogen can be used to stimulate an immune response against the pathogen in the subject. | 2009-09-03 |
| 20090220531 | Composition of which Chief Ingredient is Polysaccharides Having an Immunoregulatory Function - An object is to establish a method of preparation of novel polysaccharides from a cassis polysaccharide (CAPS), wherein the novel polysaccharides exhibit a higher immunoregulatory effect per unit amount, have a low viscosity, and can be handled readily during the method of preparation a final product. Another object is to provide health foods and drinks having high safety and an excellent immunoregulatory effect at a low cost by utilizing a juice, processed juice or a purified product. The present invention relates to a composition of which chief ingredient is novel polysaccharides, having an average molecular weight falling within a range of 10,000 to 40,000; which is obtained by partially digestion of CAPS with enzyme, and an immunoregulatory foods and drinks utilizing the composition. | 2009-09-03 |
| 20090220532 | Agents and methods based on the use of the eda domian of fibronectin - This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent. | 2009-09-03 |
| 20090220533 | Novel T-Helper Antigenic Determinant (THD) Peptides - The invention relates to a chimeric peptide, which can bind to at least one allelic form of the HLA-DR molecule. The invention also relates to a pharmaceutical composition containing said peptide, as well as to the different uses of same. | 2009-09-03 |
| 20090220534 | METHODS FOR IDENTIFYING T-CELL EPITOPES ASSOCIATED WITH IMPAIRED PEPTIDE PROCESSING AND APPLICATIONS OF THE IDENTIFIED EPITOPES - The current invention provides methods for the identification of antigens and/or epitopes that are differentially displayed on TAP deficient or TAP impaired cells and are not detectably displayed on normal or TAP proficient cells. The identification and applications of these differentially presented antigens, which in this specification are referred to as TEIPP, T cell Epitopes associated with Impaired Peptide Processing, is a prime object of this invention. The invention also provides peptides comprising a TEIPP epitope obtained from the methods of the invention, which may be applied in medicaments and methods of treatment raising a T cell response against TAP deficient tumor cells or virally infected cells. | 2009-09-03 |
| 20090220535 | THERAPEUTIC AND PROPHYLACTIC VACCINE FOR THE TREATMENT AND PREVENTION OF PAPILLOMAVIRUS INFECTION - Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions are also disclosed. | 2009-09-03 |
| 20090220536 | HIV vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-HIV-1 antibodies against the membrane proximal domain of HIV GP41 - This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions. | 2009-09-03 |
| 20090220537 | VACCINE DELIVERY SYSTEM - An isolated protein comprising a hepatitis B surface antigen (HBsAg) amino acid sequence, and encoding nucleic acid, are provided wherein one or more immunogenic T cell epitopes of the HBsAg are respectively substituted with one of more immunogenic T cell epitopes of a protein other than HBsAg. Typically, the T cell epitopes are of a pathogen or tumour protein. The isolated protein may have endogenous HBsAg epitopes substituted with multiple copies of the same epitope or with different HBsAg epitopes. B cell epitopes may also be present. Also provided are expression constructs, VLPs, compositions, vaccines and methods of treatment that may be useful in the prophylactic and/or therapeutic treatment of diseases including human papillomavirus, respiratory syncytial virus, human immunodeficiency virus (HIV), cytomegalovirus (CMV), Epstein Barr virus (EBV), rotavirus, hepatitis B virus, parainfluenza virus, hepatitis C virus, | 2009-09-03 |
| 20090220538 | VACCINE FOR STAPHYLOCOCCAL INFECTIONS - The present invention describes method of preparation and use of polypeptide vaccine formulation for prevention and control of Staphylococci mediated infections in human, bovine and other mammals, using recombinant DNA technology. | 2009-09-03 |
